Zevra Therapeutics to Present Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at Sleep Europe 2024

Stock Information for Zevra Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Zevra Therapeutics Inc.

Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD
Zevra Therapeutics, Inc. Announces CFO Transition
Zevra Reports Third Quarter 2025 Financial Results and Corporate Update
Zevra Therapeutics to Participate in the Guggenheim Healthcare Innovation Conference
Zevra Therapeutics Announces Details for Q3 2025 Financial Results Call
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Zevra Therapeutics Presents Positive New Data Supporting Foundational Role of MIPLYFFA® (arimoclomol) for the Treatment of Niemann-Pick Disease Type C at the International Congress of Inborn Errors of Metabolism (ICIEM)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.